CenExel, a Salt Lake City-based clinical research company, has acquired iResearch, a multi-specialty research site business with locations in Decatur and Savannah, Georgia. To now be known as CenExel iResearch, the acquired company does clinical trials in psychiatry (depression, bipolar disorder and schizophrenia), neurology (Alzheimer’s disease, dementia, sleep disorders), vaccine, women’s health and dermatology.{mprestriction ids="1,3"}
The acquisition of iResearch strengthens CenExel’s central nervous system trial capabilities in the psychiatry and neurology therapeutic areas, while also bolstering CenExel’s dermatology expertise, the company said.
CenExel iResearch operates in over 30,000 square feet of state-of-the-art clinical research space, including a 40-bed, 10,000-square-foot inpatient unit in Atlanta. CenExel iResearch is led by co-founders Heather Beitz and Sara Castle, who serve as CEO and chief operating officer, respectively. Dr. Kimball Johnson serves as the organization’s medical director as part of the CenExel iResearch team of 10 principal investigators.
The CenExel Centers of Excellence clinical research site network now comprises 15 clinical research sites in the country, with special emphasis on psychiatry, neurology, pain, vaccines/immunology, dermatology, ethnic-bridging, sleep and clinical pharmacology.
“The CenExel iResearch team has a long track record of delivering outstanding patient recruitment, retention and high-quality clinical data on behalf of patients and sponsors alike,” said Tom Wardle, CenExel CEO. “We are thrilled to be partnering with Heather Beitz, Sara Castle, Dr. Johnson and the entire CenExel iResearch team to further strengthen the CenExel network.”
“CenExel has an exceptional team of clinical trial and CNS-focused research experts,” said Beitz. “We’re excited to leverage CenExel’s site network infrastructure to pursue future growth opportunities together and serve more patients throughout Georgia.”{/mprestriction}
